ARID1A and melanoma: Our data show that patients with ARID1A mutated melanoma treated with immunotherapy exhibit no better overall survival than those with ARID1A-wild-type melanoma and within the ARID1A mutated cohort, no differences between inactivating and other ARID1A mutations in terms of both overall- and progression-free survival were apparent.